09/02/2026
For patients facing certain cancers or immune conditions, clinicians turn to their white blood cells for clues about the progression of disease and treatment. Peripheral blood mononuclear cells, or PBMCs, are part of the standard blood draw.
The Skala Lab at the Morgridge Institute and the UW-Madison Department of Biomedical Engineering are out with a new study asking the question: “What can we get from (PBMCs) that we aren’t already getting?”
Led by graduate student Jeremiah Riendeau, the study, for the first time, accurately observes the metabolic state of single immune cells across complex PBMC samples using a nondestructive analysis called optical metabolic imaging.
“Part of the research that’s being done here is making this label-free metabolic information accessible to more labs,” says Riendeau. “Our lab and collaborators are in the process of commercializing our technology so we can make this measurement more available.”
In the process, they hope to help improve diagnosis and treatment of immune system-related conditions like blood cancers, lupus, sepsis, and cognitive decline. PBMCs are also the starting material for CAR T cell therapies, which engineer a patient’s own immune cells to fight certain cancers.
Learn more here: https://morgridge.org/story/new-imaging-technique-reveals-the-inner-workings-of-immune-cells/
Image: Metabolically quiescent (left) and activated (right) peripheral blood mononuclear cells captured with optical metabolic imaging. Jeremiah Riendeau/Skala Lab.